New hope for tough blood cancers: first human trial begins

NCT ID NCT06291220

Summary

This is a very early-stage study to test the safety and find the right dose of a new oral drug called ABBV-453 for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or stopped responding to at least two prior treatments. Participants will first receive an IV drug to reduce cancer cells, then take escalating doses of ABBV-453. The main goals are to see what side effects occur and how the body processes the drug, while also checking if it helps control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Atrium Health /ID# 265136

    Charlotte, North Carolina, 28204-2963, United States

  • Austin Health /ID# 256776

    Heidelberg, Victoria, 3084, Australia

  • Azienda Ospedaliera di Perugia - Ospedale S. Maria della Misericordia /ID# 263062

    Perugia, 06156, Italy

  • Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin /ID# 263433

    Berlin, 12203, Germany

  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 267158

    Irvine, California, 92618, United States

  • City of Hope /ID# 253904

    Duarte, California, 91010, United States

  • Duplicate_Duke Cancer Center /ID# 258707

    Durham, North Carolina, 27710-3000, United States

  • Gold coast University Hospital /ID# 255785

    Southport, Queensland, 4215, Australia

  • Hadassah Medical Center-Hebrew University /ID# 254721

    Jerusalem, Jerusalem, 91120, Israel

  • IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 263065

    Bologna, 40138, Italy

  • IRCCS Ospedale San Raffaele /ID# 263064

    Milan, Milano, 20132, Italy

  • Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana /ID# 264622

    Billings, Montana, 59102, United States

  • MD Anderson Cancer Center /ID# 253713

    Houston, Texas, 77030, United States

  • Royal Perth Hospital /ID# 256464

    Perth, Western Australia, 6000, Australia

  • Royal Prince Alfred Hospital /ID# 263129

    Sydney, New South Wales, 2050, Australia

  • The Chaim Sheba Medical Center /ID# 254383

    Ramat Gan, Tel Aviv, 5265601, Israel

  • Universitaetsklinikum Halle (Saale) /ID# 263299

    Halle, Saxony-Anhalt, 06120, Germany

  • Universitaetsklinikum Hamburg-Eppendorf /ID# 263730

    Hamburg, 20246, Germany

  • Universitaetsklinikum Schleswig-Holstein - Campus Kiel /ID# 263150

    Kiel, Schleswig-Holstein, 24105, Germany

  • Universitaetsklinikum Ulm /ID# 263148

    Ulm, Baden-Wurttemberg, 89081, Germany

  • Yitzhak Shamir Medical Center /ID# 257626

    Ẕerifin, Central District, 70300, Israel

Conditions

Explore the condition pages connected to this study.